SOLV
Solventum Corp.
NYSE: SOLV · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$66.49
-1.51% today
Updated 2026-04-29
Market cap
$11.54B
P/E ratio
7.49
P/S ratio
1.39x
EPS (TTM)
$8.88
Dividend yield
—
52W range
$62 – $88
Volume
1.3M
Solventum Corp. (SOLV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.28B | $8.17B | $8.13B | $8.20B | $8.25B | $8.32B |
| Revenue growth (YoY) | — | +12.2% | -0.5% | +0.8% | +0.7% | +0.9% |
| Cost of revenue | $2.97B | $3.25B | $3.44B | $3.50B | $3.66B | $3.87B |
| Gross profit | $4.32B | $4.92B | $4.70B | $4.69B | $4.59B | $4.45B |
| Gross margin | 59.3% | 60.2% | 57.7% | 57.3% | 55.6% | 53.5% |
| R&D | $719.00M | $766.00M | $767.00M | $758.00M | $775.00M | $739.00M |
| SG&A | $2.17B | $2.28B | $2.23B | $2.32B | $2.78B | $3.08B |
| Operating income | $1.43B | $1.88B | $1.69B | $1.69B | $1.04B | $2.18B |
| Operating margin | 19.6% | 23.0% | 20.8% | 20.6% | 12.6% | 26.2% |
| EBITDA | $2.03B | $2.48B | $2.27B | $2.23B | $1.53B | $2.55B |
| EBITDA margin | 27.9% | 30.3% | 27.9% | 27.2% | 18.5% | 30.6% |
| EBIT | $1.43B | $1.88B | $1.69B | $1.67B | $972.00M | $2.06B |
| Interest expense | — | — | $0.00 | $0.00 | $367.00M | $347.00M |
| Income tax | $302.00M | $422.00M | $349.00M | $321.00M | $127.00M | — |
| Effective tax rate | 21.0% | 22.4% | 20.6% | 19.3% | 21.0% | 0.0% |
| Net income | $1.14B | $1.46B | $1.34B | $1.35B | $479.00M | $1.56B |
| Net income growth (YoY) | — | +28.3% | -8.0% | +0.2% | -64.4% | +224.8% |
| Profit margin | 15.6% | 17.9% | 16.5% | 16.4% | 5.8% | 18.7% |